Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
28.69
-4.15 (-12.64%)
Jun 5, 2026, 2:48 PM EDT - Market open
Beam Therapeutics Employees
Beam Therapeutics had 522 employees as of March 31, 2026. The number of employees increased by 11 or 2.15% since the number was last reported on December 31, 2025.
Employees
522
Change
11
Growth
2.15%
Revenue / Employee
$314,197
Profits / Employee
-$126,398
Market Cap
2.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 522 | 11 | 2.15% |
| Dec 31, 2025 | 511 | 28 | 5.80% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| Arcus Biosciences | 601 |
| Crinetics Pharmaceuticals | 594 |
| Denali Therapeutics | 507 |
| Dyne Therapeutics | 263 |
| Relay Therapeutics | 193 |
| Tango Therapeutics | 137 |
BEAM News
- 2 days ago - Beam Therapeutics Transcript: AGM 2026 - Transcripts
- 16 days ago - Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Beam Therapeutics presents Phase 1/2 data for BEAM-302 - TheFly
- 17 days ago - Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - GlobeNewsWire
- 23 days ago - Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - PRNewsWire
- 23 days ago - Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 23 days ago - Beam Therapeutics price target lowered to $39 from $40 at Bernstein - TheFly
- 24 days ago - Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 - GlobeNewsWire